John Berriman is the Chairman of Confo Therapeutics NV, Autifony Therapeutics Ltd and Depixus SAS; and a non-executive director of Autolus Therapeutics plc (listed on NASDAQ).

He previously chaired ReNeuron Group plc (listed on AIM), Heptares Therapeutics Ltd (sold to Sosei in February 2015) and Algeta ASA (listed on the Oslo stock exchange and sold to Bayer AG in March 2014). He has also been a director of Micromet Inc. (listed on NASDAQ and sold to Amgen in 2012), Cytos AG (listed on the SIX Swiss exchange), Ablynx NV (listed on NASDAQ and sold to Sanofi in 2018), Alnylam Inc (listed on NASDAQ) and Abingworth Management – an international healthcare venture capital firm where he was involved in founding, financing and serving as a director of several biotechnology companies in Europe and the USA – many of which obtained listings on public stock exchanges. Prior to that, he spent 14 years with Celltech Group plc and was an executive member of its Board when it listed on the London Stock Exchange in 1994. 

He has a degree in Chemical Engineering from the University of Cambridge and an MBA from the London Business School.